Meeting
2022 ASCO Annual Meeting
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4).
Authors
Sergio Vazquez-Estevez
Lucus Augusti University Hospital, Lugo, Spain
Sergio Vazquez-Estevez , Ovidio Fernandez-Calvo , Teresa Bonfill-Abella , Silvia Sequero , Francisca Martínez-Madueño , Nuria Romero-Laorden , Montserrat Domenech-Santasusana , Elena Sevillano , José García Sánchez , Carlos Alvarez-Fernandez , Cristina Núñez-González
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT04186013
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4588)
DOI
10.1200/JCO.2022.40.16_suppl.4588
Abstract #
4588
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).
First Author: Richard Cathomas
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2023 ASCO Genitourinary Cancers Symposium
A prospective phase II trial of neoadjuvant sintilimab in muscle-invasive urothelial carcinoma of bladder.
First Author: Fangning Wan
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen